Medicines & Treatments
BPC-157 & TB-500 Blend (10mg/20mg)
BPC-157 Peptide, also known as Pentadecapeptide BPC-157, or Body Protection Compound 157, is a wholly synthetic peptide that is potentially linked to multiple cellular functions and is perceived to have significance in healing of experimental models of injury. It is speculated to engage with cellular communication routes, possibly affecting elements associated with rejuvenation and recuperation. A few research studies hint that BPC-157 might also possess capabilities to encourage blood vessel formation and regulate inflammation-related activities.(1) Moreover, experimental findings have posited that BPC-157 may aid in safeguarding and regenerating various cells and tissues. Overall, BPC-157 has been suggested in various studies to potentially help with healing joint, tendon, and muscle tissue, as well as nerve tissue. TB-500 Peptide, also known as Synthetic thymosin beta-4, or TB-4, has been suggested by researchers to possibly assist in the healing process after injury, especially brain and neurological injury. Other TB-500 research has suggested it helps with wound healing and with hair growth. The peptide is a man-made variant of the thymosin beta-4 (Tβ4) peptide found naturally within the cells of the thymus organ, and encoded by the TMSB4X gene. From research on thymosin beta-4, TB-500 appears to modulate cell movement, differentiation, and tissue healing. It is believed to engage with various cellular signaling routes to manifest its actions. Investigations further imply that TB-500 might encourage angiogenesis, as well as cellular and tissue renewal.(2) Both BPC-157 and TB-500 are synthetic polypeptides, where TB-500 is composed of 43 amino acids, and BPC-157 is composed of 15 amino acids.(3)(4) Overview Based on Tβ4 research, TB-500 has been suggested to exert potential action on cellular motility via elevating the levels of actin proteins. More specifically it has been posited to regulate the cellular actin-cytoskeleton and cellular migration by sequestering G-actin. TB-500 has a distinct amino acid segment [(17)LKKTETQ(23)] which is hypothesized to be responsible for actin binding and potentially enhancing cellular motility. This in turn may exhibit positive action on wound healing processes.(5) TB-500 also seems to amplify the presence of microRNA-146a (miR-146a), which may act as a repressive regulator for certain cellular signaling routes such as those related to the activity of two inflammation-related cytokines called L-1 receptor-linked kinase 1 (IRAK1) and tumor necrosis factor receptor-linked factor 6 (TRAF6). This suggestion was further insisted as a potential mechanism of TB-500 by the authors of the research study, who also commented that "transfection of anti-miR-146a nucleotides reversed the inhibitory effect of Tβ4 on IRAK1 and TRAF6." Thus, TB-500 also appears to potentially work for healing by exerting anti-inflammatory action.(6) BPC-157 peptide has been suggested to exert some action via various processes encompassing nitric oxide production, control of cells pertinent to tissue restoration, growth elements, and inflammatory responses. It is conceivable that BPC-157 may exhibit some engagement with the NO mechanism, possibly providing a safeguard for the endothelium and perhaps encouraging angiogenic behaviors by fostering the development of new circulatory routes. Researchers suggest there is a chance it may boost the expression of the early growth response 1 gene, which may play a role in producing cytokines and growth stimuli, and possibly aid in the initial assembly of the extracellular framework, inclusive of collagen. It is worth highlighting that BPC-157's relation with nerve growth factor 1-A binding protein-2 may exert inhibitory action on specific elements.(7) As a result, new tissues composed of collagen may be formed, thereby possibly enhancing the healing of wounds more rapidly.(8) As both TB-500 and BPC-157 peptides appear to exhibit similar pharmacological potential, when blended together, the potential action of both may be maximized – what would otherwise occur with one peptide, might occur at a better, faster rate when combined. Chemical Makeup Molecular Formula: BPC-157: C62H98N16O22 TB-500: C212H350N56O78S Molecular Weight: BPC-157: 1419.5 g/mol TB-500: 4963 g/mol Other Known Titles BPC-157: Body Protection Compound-157 TB-500: Thymosin Beta-4 Research and Clinical Studies There are no research or clinical studies currently available where both TB-500 and BPC-157 were used in the same experiment or presented in combination, using the same test model. However, below listed are the studies observing the potential action of the individual peptides. BPC-157 & TB-500 Blend and Tissue Repair In one study with Tβ4 conducted in 1999,(9) experimentally wounded murine models were used as subjects, where half the number of murine models were presented with saline and the rest were presented with TB-500 peptide. The main aim of this study was to determine the potential tissue repair action of the peptide. Four days after the experiment, it was reported by the researchers that the murine models presented with TB-500 showed an apparent 41% increment in the re-epithelialization process (i.e., formation of new epithelial cells to resurface the wound). After seven days, the wounds presented with TB-500 had reportedly contracted by at least 11% as compared to the saline wounds. The authors commented that “these results suggest that Tβ4 is a potent wound healing factor with multiple activities...” In another 2006 clinical trial,(10) 72 test subjects with pressure ulcers were presented with TB-500. The main aim of this randomized, double blind study was to establish the potential of thymosin beta 4 (analogous to TB-500) in ulcer presence. The test subjects were divided into two groups, where one group was presented with placebo for 84 days and the rest were presented daily with various concentrations of the peptide, for up to 84 days. After 84 days, there was an occurrence of wound healing process where the ulcers reportedly exhibited signs of healing. In a BPC-157 study,(11) three experimental murine models were used as subjects where all were experimentally wounded, with either acute or chronic wounds. These murine models were then divided into two groups, where one was presented with a placebo compound and the other was presented with BC-157 peptide. After the experiment, all the murine models were histologically examined, and it was determined that the murine models with BPC-157 exhibited a prominently higher number of collagen and blood vessels formed as compared to the placebo murine models. BPC-157 & TB-500 Blend and Ligaments In one study,(12) the medial collateral ligament (MCL) of the murine models was transected (cut across) during surgery. All the murine models were then presented with a fibrin sealing agent, where some murine models were also presented with thymosin beta 4 (TB-500). Four weeks after the surgery, it was reported by the researchers that the healing tissues in the peptide murine models exhibited apparently evenly formed and spaced collagen cells. The collagen cells formed in the peptide murine models were reportedly wider as compared to the control murine models. Furthermore, the mechanical properties of the regenerating tissues, including the femur-medial collateral ligament-tibia complexes, appeared to be improved in the TB-500 group compared to the control. Another research article indicated that BPC-157 might play a role in aiding the recovery of connective tissues, potentially by promoting the growth of tendon explants. Interestingly, the study suggested that BPC-157 may possibly enhance the resilience of these cells in the face of oxidative stress. This outcome might be linked to the triggering of F-actin formation, as indicated by FITC-phalloidin staining. BPC-157 also appeared to enhance the in vitro movement of tendon fibroblasts as indicated by a transwell filter migration test. Furthermore, BPC-157 appeared to hasten the dispersion of tendon fibroblasts across culture plates. Additionally, the study delved into the possible role of the FAK-paxillin pathway (a pair of focal adhesion-linked proteins that relay signals following integrins) in conveying the action of BPC-157. Western blot tests hinted that the phosphorylation rates of both FAK and paxillin seemed to rise with BPC 157, yet the overall protein quantities stayed constant.(8) BPC-157 & TB-500 Blend and Muscle A study(13) was conducted on murine models with experimentally injured gastrocnemius muscle complex. These murine models were initially presented with corticosteroids, which reportedly contributed to severe muscular damage in these murine models . These murine models were then divided into two groups, where one was presented with placebo and the other with BPC-157 daily for up to 14 days. After the experiment, it was reported that the BPC-157 murine models appeared to exhibit complete restoration of their gastric muscles along with full ability to function. Whereas, the placebo treated group did not exhibit any apparent change to the damaged muscles. TB-500 may also have a potential effect on muscle cell regeneration, more specifically on cardiac muscle cells. One study suggests that TB-500 appears to bolster myocardial resilience in conditions of low oxygen, and seemingly fosters angiogenesis, possibly paving the way for cardiac cell repair. Researchers have hinted at a potential process where cardiac fibroblasts transition into cells resembling cardiomyocytes.(14) In the end, the scholars observed that TB-500, when combined with cardiac reprogramming techniques, might collaboratively reduce potential harm to cardiac cells and foster its regeneration by activating inherent cells within the cardiac region. An examination using murine models of coronary artery tying appeared to exhibit results which implied that TB-500 might elevate integrin-associated kinase (ILK) and protein kinase B operations in the heart, possibly boosting early cardiomyocyte endurance and seemingly enhancing heart performance.(15) The experts also suggested that TB-500 might support the movement of myocardial and endothelial cells in the fetal heart and maintains this capability in mature cardiomyocytes. BPC-157 & TB-500 Peptide Blend is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Seiwerth, S., Milavic, M., Vukojevic, J., Gojkovic, S., Krezic, I., Vuletic, L. B., Pavlov, K. H., Petrovic, A., Sikiric, S., Vranes, H., Prtoric, A., Zizek, H., Durasin, T., Dobric, I., Staresinic, M., Strbe, S., Knezevic, M., Sola, M., Kokot, A., Sever, M., … Sikiric, P. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in pharmacology, 12, 627533. https://doi.org/10.3389/fphar.2021.627533 Maar, K., Hetenyi, R., Maar, S., Faskerti, G., Hanna, D., Lippai, B., Takatsy, A., & Bock-Marquette, I. (2021). Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State-New Directions in Anti-Aging Regenerative Therapies. Cells, 10(6), 1343. https://doi.org/10.3390/cells10061343 National Center for Biotechnology Information. “PubChem Compound Summary for CID 132558700, CID 132558700” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/132558700 National Center for Biotechnology Information. “PubChem Compound Summary for CID 9941957” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Bpc-157 Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008 May 15;453(7193):314-21. doi: 10.1038/nature07039. PMID: 18480812. https://pubmed.ncbi.nlm.nih.gov/18480812/ Santra, M., Zhang, Z. G., Yang, J., Santra, S., Santra, S., Chopp, M., & Morris, D. C. (2014). Thymosin β4 up-regulation of microRNA-146a promotes oligodendrocyte differentiation and suppression of the Toll-like proinflammatory pathway. The Journal of biological chemistry, 289(28), 19508–19518. https://doi.org/10.1074/jbc.M113.529966 Sikiric, Predrag et al. “Brain-gut Axis and Pentadecapeptide BPC-157: Theoretical and Practical Implications.” Current neuropharmacology vol. 14,8 (2016): 857-865. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#r1 Chang, Chung-Hsun et al. “The promoting effect of pentadecapeptide BPC-157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of applied physiology (Bethesda, Md. : 1985) vol. 110,3 (2011): 774-80. doi:10.1152/japplphysiol.00945.2010. https://pubmed.ncbi.nlm.nih.gov/21030672/ Katherine M. Malinda et.al, Thymosin β4 Accelerates Wound Healing, Journal of Investigative Dermatology, Volume 113, Issue 3, 1999, Pages 364-368, ISSN 0022-202X, https://www.sciencedirect.com/science/article/pii/S0022202X15405950 Study of Thymosin Beta 4 in Patients With Pressure Ulcers. https://www.clinicaltrials.gov/ct2/show/NCT00382174 S Seiwerth, et al. “BPC-157’s effect on healing.” Journal of physiology, Paris vol. 91,3-5 (1997): 173-8. doi:10.1016/s0928-4257(97)89480-6. https://pubmed.ncbi.nlm.nih.gov/9403790/ Xu B, Yang M, Li Z, Zhang Y, Jiang Z, Guan S, Jiang D. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regul Pept. 2013 Jun 10;184:1-5. doi: 10.1016/j.regpep.2013.03.026. https://pubmed.ncbi.nlm.nih.gov/23523891/ Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, Mise S, Brcic I, Kolenc D, Klicek R, Banic T, Sever M, Kocijan A, Berkopic L, Radic B, Buljat G, Anic T, Zoricic I, Bojanic I, Seiwerth S, Sikiric P. Impact of pentadecapeptide BPC-157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010 Mar;16(3):BR81-88. PMID: 20190676. https://pubmed.ncbi.nlm.nih.gov/20190676/ Srivastava, D., Ieda, M., Fu, J., & Qian, L. (2012). Cardiac repair with thymosin β4 and cardiac reprogramming factors. Annals of the New York Academy of Sciences, 1270, 66–72. https://doi.org/10.1111/j.1749-6632.2012.06696.x Bock-Marquette, I., Saxena, A., White, M. D., Dimaio, J. M., & Srivastava, D. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472. https://doi.org/10.1038/nature03000 { "@context": "https:\/\/schema.org", "@type": "Product", "name": "BPC-157 & TB-500 Blend (10mg)", "description": "BPC-157 & TB-500 blend for sale online (10mg). Peptides for sale at 99% purity with top customer service. Read about research study results and information.", "image": "https://www.painandanxietymeds.shop/wp-content/uploads/2020/04/BPC-157-TB-500-5-5MG-300x300.jpg", "offers": [ { "@type": "Offer", "priceCurrency": "USD", "price": 105, "availability": "https:\/\/schema.org\/InStock", "itemCondition": "https:\/\/schema.org\/NewCondition", "seller": { "@type": "Organization", "name": "painandanxietymeds.shop" }, "url": "https:\/\/www.painandanxietymeds.shop\/bpc-157-tb-500-10mg-blend/", "hasMerchantReturnPolicy": { "@type": "MerchantReturnPolicy", "applicableCountry": "US", "returnPolicyCategory": "https:\/\/schema.org\/MerchantReturnNotPermitted" }, "shippingDetails": { "@type": "OfferShippingDetails", "shippingRate": { "@type": "MonetaryAmount", "minValue": 0, "maxValue": 9.25, "currency": "USD" }, "shippingDestination": { "@type": "DefinedRegion", "addressCountry": "US" }, "deliveryTime": { "@type": "ShippingDeliveryTime", "handlingTime": { "@type": "QuantitativeValue", "minValue": 1, "maxValue": 2, "unitCode": "d" }, "transitTime": { "@type": "QuantitativeValue", "minValue": 1, "maxValue": 5, "unitCode": "d" } } }, "priceValidUntil": "2027-04-09T15:10:59+00:00" } ], "url": "https:\/\/www.painandanxietymeds.shop\/bpc-157-tb-500-10mg-blend/", "aggregateRating": { "@type": "AggregateRating", "ratingValue": 98, "bestRating": 100, "reviewCount": 732 }, "review": [] } Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Fragment 176-191 (5mg)
Fragment 176-191 peptide, also known as hGH Fragment 176-191, tyr-hGH 177-191, or AOD-9604, has been suggested by researchers that it may stimulate weight loss and fat burn in a fashion similar to that of the growth hormone (hGH). hGH is a naturally occurring hormone, which, apart from stimulating growth, as the name suggests, may also stimulate catabolism of adipose tissue and the release of lipids from fat cells. Fragment 176-191 is a small ‘fragment’ of the growth hormone hGH composed of 16 amino acids. This involves the last 16 amino acids of the hGH molecule, which scientists propose to be the “lipolytic fragment” of hGH. Lipolythic, as a term, reflects the purported fat-burning properties of the molecule. To potentially improve the stability of the peptide, the first amino acid in the hGH Fragment 176-191 sequence is also replaced by tyrosine. Thus, the peptide is also labeled as Fragment tyr-hGH 177-191.(1)(2) Overview This peptide could, in theory, aim at the beta-3 adrenergic receptors (ß3-AR), which might, in turn, lead to a potential weight loss action. It is posited that through these receptors, the peptide may encourage fat burning in adipose tissue and foster 'thermogenesis' in skeletal muscle cells. In a study involving obese murine models exposed to the peptide for two weeks, there seemed to be an apparent decrease in weight, including a reduction in excess fat. These observations are thought to be linked to a rise in the activity of lipolytic beta-3 adrenergic receptors, hinting that the peptide's actions could be connected to the beta-adrenergic pathway. The researchers commented that Fragment 176-191 may be “capable of increasing the repressed levels of beta(3)-AR RNA in obese mice to levels comparable with those in lean mice.” Unfortunately, the data may not be conclusive, as the research on murine models with disabled lipolytic receptors suggested that the peptide still led to apparent weight loss, suggesting its actions might not solely rely on these receptors. Thus, it was also considered that the peptide might help burn fat through mechanisms like energy expenditure and fat oxidation, though this remains an area for further investigation.(3) As mentioned, the presence of tyrosine at the N-terminus of the fragment increases the stability of the peptide. In addition, there appears to be a naturally occurring disulfide bridge between the two cysteine amino acids in the molecule of hGH and hGH Fragment 176-191. This bridge appears to further stabilize the molecule and may increase its resistance against degradation in various environments, including stomach acid.(4)(5) Chemical Makeup Molecular Formula: C78H125N23O23S2 Molecular Weight: 1817.12 g/mol Other Known Titles: hGH Fragment 176-191; Lipolytic fragment Research and Clinical Studies Fragment 176-191 and Fat Cells As mentioned, Fragment 176-191 is believed to potentially increase fat burning through different mechanisms, which may include the upregulation of the beta-3 adrenergic receptors. More specifically, the peptide might elevate the expression levels of beta(3)-AR RNA in fat cells. This suggests that Fragment 176-191 may influence signaling pathways or transcription factors that enhance the production of beta-3 adrenergic receptor mRNA, leading to increased synthesis of the beta-3 adrenergic receptors protein. With more beta-3 adrenergic receptors present on the surface of adipocytes (fat cells), the cells may become more sensitive to lipolytic signals. This posits that even though Fragment 176-191 may not directly activate beta-3 adrenergic receptors, the increased number of receptors might amplify the natural lipolytic response to endogenous catecholamines (like adrenaline), which are suggested to engage these receptors directly. Fragment 176-191 might also activate other cellular signaling mechanisms that indirectly boost fat burning. For example, it may influence pathways that either upregulate the expression of enzymes involved in the lipolysis process or enhance the cellular response to lipolytic signals by modulating the activity of secondary messengers within the cell. This has been explored by clinical trials, the most notable of which was METAOD005. This trial was initiated to explore the possible fat-burning action of a peptide. 300 test subjects were involved in this investigation, which lasted 12 weeks. There were six groups, including one control group and five Fragment 176-191 groups. It was suggested that one of the Fragment 176-191 groups experienced an apparent decrease in body weight, potentially by around 5.7 pounds. Moreover, it was posited that the peptide may have possibly contributed to improvements in the cholesterol levels and glucose tolerance of these participants.(6) Fragment 176-191 and Cartilage Regeneration Some researchers have posited that Fragment 176-191 peptide may have some of the proposed regenerative properties of hGH, in addition to its apparent fat-burning potential. To explore these potential impacts of Fragment 176-191 peptide, researchers used a knee osteoarthritis model caused by collagenase. The experimental models were introduced with type II collagenase to apparently induce damage to the knee cartilage. Following this, for a period of 4-7 weeks, the models were split into four groups including saline (Group 1), hyaluronic acid (Group 2), Fragment 176-191 peptide (Group 3), and a combination of Fragment 176-191 peptide with hyaluronic acid (Group 4). The severity of the cartilage damage was evaluated through both morphological and histopathological analysis, and the degree of lameness was observed 8 weeks after the beginning of the trial. The researchers commented, "Mean gross morphological and histopathological scores were significantly higher in Group 1 than in Groups 2, 3, and 4, and the scores were significantly lower in Group 4 than in Groups 2 and 3. The lameness period in Group 4 was significantly shorter than those in Groups 1, 2, and 3.” This suggested that both hyaluronic acid and Fragment 176-191 peptide may be better than saline in stimulating an apparent cartilage regeneration, and the best research outcome may be achieved with a combination of Fragment 176-191 peptide and hyaluronic acid.(7) Fragment 176-191 and Hyperglycemia In one study,(8) several synthetic hGH peptides, including Fragment 176-191, were presented in normal functioning murine models to determine its potential on glycogen metabolism. Upon delivery, it was reported that the peptide appeared to induce a slight increment in levels of blood glucose and lactate, with a slight reduction in the ratio of glycogen synthase in muscle, adipose tissues, and the liver. It was suggested that this outcome was due to the peptide's apparent action of converting the enzymes from their active state to inactive state, as the total synthase levels appeared to remain at constant concentrations. Fragment 176-191 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015 Jan;7(1):31-8. doi: 10.1002/dta.1715. Epub 2014 Sep 10. PMID: 25208511. Heffernan, Mark, et al. "The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice." Endocrinology 142.12 (2001): 5182-5189. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. doi: 10.1210/endo.142.12.8522. PMID: 11713213. Stier, Heike, Evert Vos, and David Kenley. "Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans." Journal of Endocrinology and Metabolism 3.1-2 (2013): 7-15. Moré, Margret I., and David Kenley. "Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health." Journal of Endocrinology and Metabolism 4.3 (2014): 64-77. Valentino, M A et al. “Central and peripheral molecular targets for antiobesity pharmacotherapy.” Clinical pharmacology and therapeutics vol. 87,6 (2010): 652-62. doi: 10.1038/clpt.2010.57 Kwon, Dong Rak, and Gi Young Park. “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.” Annals of clinical and laboratory science vol. 45,4 (2015): 426-32. Ma GY, Macaulay SL, Maggs JA, Armstrong JM, Bornstein J. The mechanism of the hyperglycaemic action of synthetic peptides related to the C-terminal sequence of human growth hormone. Biochim Biophys Acta. 1982 Jun 16;716(3):400-9. doi: 10.1016/0304-4165(82)90033-2. PMID: 6810951. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Nonapeptide-1 (200mg)
Nonapeptide-1 is a nine amino acid peptide that was first developed in the 1990s, sparking research interest due to its potential to inhibit the synthesis of melanin, the main pigment in mammals responsible for color in the skin, fur, hair, eyes, etc. The research on Nonapeptide-1 is still in its early stages, and much is still unknown about its potential and mechanisms of action. Studies on Nonapeptide-1 have primarily focused on its potential to inhibit melanin production by interfering with the signaling pathway involved in melanogenesis. Specifically, Nonapeptide-1 is thought by researchers to possibly inhibit the melanocortin-1 receptors, which may prevent the action of melanocyte-stimulating hormones and the activation of the enzyme tyrosinase, which is necessary for the synthesis of melanin.(1) By doing so, Nonapeptide-1 may have a reducing potential on hyperpigmentation and skin tone in animal studies. Nevertheless, further studies are needed to fully understand the potential of this peptide. Chemical Makeup Molecular formula: C61H87N15O9S Molecular weight: 1206.5 g/mol Research and Clinical Studies Nonapeptide-1 Discovery and Mechanism of Action Scientists have investigated a peptide library of 31,360 structurally different melanocortin-1 receptor antagonists with the aim of finding the most potentially potent inhibitor of these receptors.(2) These melanocortin-1 receptors may be found in melanocytes, which are pigment-producing cells. One of the main agonists of these receptors is considered to be the alpha-melanocyte-stimulating hormone (α-MSH). α-MSH is a neuropeptide thought to be involved in regulating pigmentation, energy homeostasis, and immune function. The pituitary gland and the skin produce it. α-MSH may stimulate melanin production by binding to the melanocortin-1 receptor on melanocytes and activating a signaling cascade that increases tyrosinase activity and melanin production. Tyrosinase is the rate-limiting enzyme in melanogenesis.(3) In addition, α-MSH may also act as an antagonist for the agouti signaling protein (ASP), which inhibits MC1R activity and reduces melanin production. The researchers suggested that the most potent antagonist of all 31,360 peptides was Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2, aka nonapeptide-1.(2) The scientists reported that it "has an IC50 value of 11 +/- 7 nM'' and the "analysis revealed that D-Trp5 and Phe6 were crucial to its antagonistic properties which could be potentiated by D-Phe3." Nonapeptide-1 and Skin Pigmentation The potential action of Nonapeptide-1 has been researched in both clinical and laboratory settings. In one in vitro study, keratinocyte cell line (HaCaT) cells and epidermal melanocytes (HEM) were exposed to UVA and imbued with different concentrations of the acetate salt of Nonapeptide-1.(4) The scientists accessed cell viability, melanin content, and tyrosinase activity. The scientists suggested that Nonapeptide-1 downregulated melanocortin 1 receptor expression without affecting α-MSH levels, and might significantly decrease the expression of tyrosinase, TRP1 (tyrosinase-related protein-1), TRP2 (tyrosinase-related protein-2), and MITF (microphthalmia-associated transcription factor) with or without concomitant UVA radiation. Besides, the researchers further posited that cells infused with nonapeptide-1 may significantly increase the ability to resist melanin production. More recent research on nonapeptide-1 also hypothesizes that the peptide may produce an apparent skin lightening by at least 33% and suggested a continued improvement over time.(5) The only clinical trial on the topic was a prospective double-blinded parallel-group randomized controlled pilot study that lasted eight months and had three phases.(6) The researchers reported an apparent improvement in severity scores of melasma and mean melanin index. They also commented, "The melasma area and severity index score showed a consistent reduction in the case group, whereas it increased in the control group from baseline." Nonapeptide-1 and Future Research Potential Apart from melanocytes, the melanocortin 1 receptors that Nonapeptide-1 potentially inhibits may be expressed in other cells, such as nerve cells and immune cells. More specifically, the melanocortin 1 receptors may be found in the periaqueductal gray matter, which plays a major role in nociception.(7) Scientists have conducted experiments on mice with overexpression of an endogenous antagonist of the melanocortin 1 receptor compared to control mice.(8) They tested their response to painful and non-painful stimuli and their response to inflammatory and neuropathic pain. Additionally, they tested their aversion to capsaicin, which may activate the TRPV1 noxious heat receptor, using a paired preference paradigm. The scientists indicated that mice overexpressing the melanocortin 1 receptor antagonist exhibited an apparently reduced inflammatory pain response and a slower onset of inflammation-induced hypersensitivity and allodynia. They were also observed to exhibit a decreased aversion to moderate concentrations of capsaicin. The scientists highlighted that these results occurred only in female mice and that "mice of either sex did not show any effect of mutant genotype on neuropathic pain." Studies also suggest that melanocortin 1 receptors may play a role in the growth and survival of melanoma tumor cells.(9) Melanoma is a type of skin cancer with a high mortality rate, and mutations in the melanocortin 1 receptor gene may be associated with changes in the risk of developing melanoma. In this study, the researchers inhibited melanocortin 1 receptors using natural inhibitors, which reduced melanin synthesis and morphological heterogeneity in murine B16-F10 melanoma cells. They found that the inhibition resulted in slower tumor cell growth and a more homogeneous size and morphology of the tumors. The study suggests that melanocortin 1 receptors may play an important role in regulating melanoma growth and morphology, and persistent inhibition of melanocortin 1 receptors may significantly slow the growth rate of the tumor cells that express these receptors. Nonapeptide-1 hasn't been researched regarding its potential impact on melanoma tumor cells. Nonapeptide-1 is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Dhatt S (2006) Rebuilding the dermal matrix with this new in-demand ingredient in skin care products. Aesthetic Trends Technol 17–20 Jayawickreme, C. K., Quillan, J. M., Graminski, G. F., & Lerner, M. R. (1994). Discovery and structure-function analysis of alpha-melanocyte-stimulating hormone antagonists. Journal of Biological Chemistry, 269(47), 29846-29854. Gaston, L. S., & Majzoub, J. A. (2022). Adrenocorticotrophin. In The Pituitary (pp. 51-89). Content Repository Only!. Chen, J., Li, H., Liang, B., & Zhu, H. (2022). Effects of tea polyphenols on UVA-induced melanogenesis via inhibition of α-MSH-MC1R signalling pathway. Postepy dermatologii i alergologii, 39(2), 327–335. https://doi.org/10.5114/ada.2022.115890 Mohammed, Y. H., Moghimi, H. R., Yousef, S. A., Chandrasekaran, N. C., Bibi, C. R., Sukumar, S. C., Grice, J. E., Sakran, W., & Roberts, M. S. (2017). Efficacy, Safety and Targets in Transdermal Active and Excipient Delivery. Percutaneous Penetration Enhancers Drug Penetration Into/Through the Skin: Methodology and General Considerations, 369–391. https://doi.org/10.1007/978-3-662-53270-6_23 Chatterjee, M., Neema, S., & Rajput, G. R. (2021). A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance. Indian journal of dermatology, venereology and leprology, 88(1), 51–58. https://doi.org/10.25259/IJDVL_976_18 Xia, Y., Wikberg, J. E., & Chhajlani, V. (1995). Expression of melanocortin 1 receptor in periaqueductal gray matter. Neuroreport, 6(16), 2193-2196. Delaney, A., Keighren, M., Fleetwood-Walker, S. M., & Jackson, I. J. (2010). Involvement of the melanocortin-1 receptor in acute pain and pain of inflammatory but not neuropathic origin. PloS one, 5(9), e12498. https://doi.org/10.1371/journal.pone.0012498 Kansal, R. G., McCravy, M. S., Basham, J. H., Earl, J. A., McMurray, S. L., Starner, C. J., Whitt, M. A., & Albritton, L. M. (2016). Inhibition of melanocortin 1 receptor slows melanoma growth, reduces tumor heterogeneity and increases survival. Oncotarget, 7(18), 26331–26345. https://doi.org/10.18632/oncotarget.8372 Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Thymalin (25mg)
Thymalin is a polypeptide isolated from the thymus gland, believed by researchers to help regulate immune functions.(2) Studies have suggested that Thymalin, a naturally occurring polypeptide, is primarily found in the young epidermal cells of the thymus gland. With increasing age, the levels of Thymalin decrease, eventually becoming thinned out and non-uniform in nature.(5) Natural thymic peptides such as Thymalin were first isolated from the thymus gland via a mild acid extraction process. Upon further isolation studies, the proposed immunomodulatory molecule composed by Thymalin (L-Glu-L-Trp) was discovered and researched. This dipeptide molecule in Thymalin may possibly play a role in the peptide mechanism.(4) While both Thymalin and Thymulin are naturally occurring thymic factors, their mode of action is hypothesized by researchers to different, where Thymalin is a polypeptide that may regulate thymic functions at optimal levels, the Thymulin appears to be a zinc-dependent nonapeptide hormone that may possibly enhance the thymic functions in fighting T-cell suppression. Overview Studies have been conducted to understand the functioning of both natural and synthetic thymic peptides.(6) The main compounds that have been studied areThymalin (natural polypeptide), Thymogen (synthetic peptide) and Vilon (its derived dipeptide). The study suggested that all the peptides within this thymic family appear to function via possibly stimulating thymic functions i.e., differentiation of T-cells, induced changes in the nucleotides and cytokine cells and secretion of lymphocytes. The other significant hypothesis made during this study was that the naturally occurring peptide, Thymalin, may potentially stimulate the antioxidant responses, whereas the two synthetic analogues did not appear to the researchers to alter these responses. Thymalin, being a natural extract, possibly exhibits a broader range of biological activities compared to its synthetic counterparts, Thymogen and Vilon. For instance, by potentially aiding in the reduction of oxidative stress, Thymalin might contribute indirectly to controlling inflammatory responses, which are typically exacerbated by oxidative damage. Chemical Makeup Molecular Formula: C33H54N12O15 Molecular Weight: 858.864 g/mol Other Known Titles: Thymulin, Thymic Factor Research and Clinical Studies Thymalin and Carcinogenesis In this study,(7) 76 female rats of 5 months of age were selected. The main aim of this study was to determine the potential of Thymalin on the tumor development and thereby survival rates of the test models. The rats were divided into two groups, where 32 rats were presented with saline, and the remaining rats were presented with Thymalin. The compounds were introduced to the test subjects 5x a week for one year. All rats were monitored for mortality rates and development of tumors throughout the one-year period. The study results reported that the average lifespan in the control group was 949 days whereas in the peptide group was 1048 days. The "aging rate" was reported as 0.0071 days in the control group and 0.0041 in the peptide group. What's more, the tumor incidence reportedly decreased by 1.5x in the peptide group as compared to the control group. It is plausible that the reduction in tumor occurrence was even more significant for hematopoietic cancer cells, with incidences appearing to be approximately 3.4 times lower in murine models exposed to the peptide. This observation might indicate that the peptide could influence key elements of the immune system essential for inhibiting cancer cell development and its progression. Subsequent inquiries into the mechanisms underlying these observations might show that the L-Glu-L-Trp in Thymalin is linked with improved differentiation of T-cumin, which are critical components of the adaptive immune system. This process may enhance the ability of these cells to identify complexes of peptides and major histocompatibility complex (MHC) molecules. Furthermore, noticeable alterations were observed in the levels of cyclic nucleotides within the cells, which play roles in cellular signaling processes. Additionally, there was an activation of neutrophil chemotaxis and phagocytosis, processes involved in the first-line defense against pathogens and potentially malignant cells. Furthermore, analysis of the study's data demonstrated that L-Glu-L-Trp was quickly absorbed, attaining notable concentrations in tissues such as the liver and lymph nodes. The presence of the peptide in these pivotal locations might enable a more efficient immune response, which could be a factor in the observed scientific findings. Thymalin and Viral Infection In this clinical study,(8) 50 female test subjects with HHV 1 and a group of control subjects were examined. All the subjects were presented with thymic peptides similar to Thymalin for a period of 2 months. Before and after the study, peripheral blood cell tissues were collected from the subjects and examined to monitor the cytokine levels upon peptide presentation. Upon analysis, it was determined that compared to the control group, the cytokine levels were elevated in a higher proportion in the HHV 1 group. The levels of cytokines CD4+ and CD8+ were reportedly elevated in the HHV 1 group as compared to the control. Additionally, researchers reported that after a two-month period, no reactivation of the HHV 1 virus was reported in the test group. Further analysis was conducted to understand the potential mechanisms through which thymic peptides may influence immune exhaustion markers and cytokine levels. The study reported changes in the expression of the exhaustion markers PD-1 and PD-L1 on both T and B lymphocytes. Post-exposure measurements indicated a notable decrease in the co-expression of these markers, suggesting a potential revitalization of immune response capabilities in the subjects. Moreover, the specific increase in the levels of IFN-γ and IL-2 related to thymic peptides suggests a targeted enhancement of Th1 immune responses, which are crucial for antiviral defense. This action was observed without significant changes in the levels of IL-4 and IL-10, indicating that thymic peptides might selectively promote a type of immune response that is more effective against viral infections, without broadly elevating all aspects of immune activation. Thymalin and Toxic Goiter Models In this clinical study,(9) 104 test subjects with mild Diffuse Toxic Goiter (DTG) were enrolled, and their levels of medium weight molecular peptides and lipid oxidation rates were monitored. The main aim of this study was to establish the potential of Thymalin in interacting with DTG. The test subjects were divided into five groups where each group was presented with an external compound, a combination of Thymalin and an external compound, or the peptide alone. Following the study, it was reported that a combination of compounds and Thymalin exhibited mitigation of DTG symptoms in the test subjects. Thymalin and Lympholeukemia Models In this clinical study,(12) test subjects with chronic lymphoid leukemia were enrolled in the inclusion study composed of specific and nonspecific immune correction action, namely Thymalin presentation and plasmapheresis, respectively. Compared to the sole impact of chemotherapeutic agents, this combined presentation apparently resulted in a reported increase in physiological functioning within a short period. Thymalin and Geroprotection In this test study,(13) the geroprotective potential of Thymalin (thymic peptide) and Epithalamin (pineal peptide) were studied on 266 mature test subjects for a period of 6 to 8 years. The subjects were presented with the peptides for the first 2 to 3 years and were then monitored on a regular basis. The subjects were divided into several groups: Group I was presented with Thymalin, Group II with Epithalamin, Group III with both peptides and a separate group where test subjects were presented with both peptides at a different concentration rate. The peptides were presented to the test models annually for 6 years. The studies suggested that basic functions improved significantly upon study under both the peptides, including cardiovascular, neurological, immunological functions and that the peptide possibly improved rates of metabolism and hemostasis. It is posited that Thymalin may contribute to the maintenance or possibly the rejuvenation of thymic function, which typically declines gradually. This action on thymic function might explain the observed improvements in T-cell mediated immunity. Researchers noted a potential restoration of both the quantity and functionality of T-cells, which are critical for adaptive immunity. Additionally, Thymalin may exert actions on systemic inflammation, a common feature in aging models. The study hinted at a possible reduction in markers of systemic inflammation in subjects exposed to Thymalin. This observation aligns with the hypothesized role of Thymalin in modulating cytokine production and immune cell regulation, which may collectively contribute to a reduction in chronic inflammation. The potential influence of Thymalin on stress hormones, particularly cortisol, was another focal point of the study. Thymalin might potentially modulate the hypothalamic-pituitary-adrenal (HPA) axis to stabilize cortisol levels, thereby mitigating some of the adverse actions of stress. In terms of metabolic actions, subjects exposed to Thymalin showed potential improvements in metabolic stability. Researchers observed a possible normalization of metabolic parameters such as glucose and lipid profiles. These changes could be indicative of Thymalin's influence on metabolic processes, possibly through enhancement of cellular metabolism or through direct actions on metabolic enzymes. Thymalin peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Disorders of the Immune system. https://www.hopkinsmedicine.org/health/conditions-and-diseases/disorders-of-the-immune-system Khavinson VK, Linkova NS, Kvetnoy IM, Polyakova VO, Drobintseva AO, Kvetnaia TV, Ivko OM. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bull Exp Biol Med. 2020 Nov;170(1):118-122. doi: 10.1007/s10517-020-05016-z. Epub 2020 Nov 25. https://pubmed.ncbi.nlm.nih.gov/33237528/ Remien K, Jan A. Anatomy, Head and Neck, Thymus. [Updated 2021 Feb 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK539748/ Morozov VG, Khavinson VK. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. 1997 Sep-Oct;19(9-10):501-5. doi: 10.1016/s0192-0561(97)00058-1. https://pubmed.ncbi.nlm.nih.gov/9637345/ Khlystova, Z.S., Kalinina, I.I., Shmeleva, S.P. et al. Age-Related Changes of Thymalin Content in Human Epidermis. Bulletin of Experimental Biology and Medicine 133, 620–622 (2002). https://doi.org/10.1023/A:1020214816056 V.G. Morozov, V.Kh. Khavinson, Natural and synthetic thymic peptides as therapeutics for immune dysfunction, International Journal of Immunopharmacology, Volume 19, Issues 9–10, 1997, Pages 501-505. https://www.sciencedirect.com/science/article/abs/pii/S0192056197000581 Anisimov VN, Khavinson VK, Morozov VG. Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology. 2000;1(1):55-9. https://pubmed.ncbi.nlm.nih.gov/11707921/ Hymos A, Grywalska E, Klatka J, Klatka M, Korona-Głowniak I, Roliński J. ThymicPeptides Reverse Immune Exhaustion in Patients with Reactivated Human Alphaherpesvirus1 Infections. Int J Mol Sci. 2020 Mar 30;21(7):2379. https://pubmed.ncbi.nlm.nih.gov/32235584/ Iangolenko VV. The effect of combined therapy with the use of thymalin and piracetam on the level of middle-molecule peptides in the blood and on the lipid peroxidation activity in patients with diffuse toxic goiter. Ter Arkh. 1991;63(10):60-3. Russian. https://pubmed.ncbi.nlm.nih.gov/1725225/ Khavinson, V., Linkova, N., Dyatlova, A., Kuznik, B., & Umnov, R. (2020). Peptides: Prospects for Use in the Treatment of COVID-19. Molecules (Basel, Switzerland), 25(19), 4389. https://doi.org/10.3390/molecules25194389 Khavinson, V. K., Linkova, N. S., Kvetnoy, I. M., Polyakova, V. O., Drobintseva, A. O., Kvetnaia, T. V., & Ivko, O. M. (2020). Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bulletin of experimental biology and medicine, 170(1), 118–122. https://doi.org/10.1007/s10517-020-05016-z Tretiak NN, Babenko TF, Gaĭdukova SN, Zverkova AS, The efficacy of using thymalin and plasmapheresis in the combined treatment of patients with chronic lympholeukemia. Lik Sprava. 1998 Mar-Apr;(2):93-6. Russian. https://pubmed.ncbi.nlm.nih.gov/9670669/ Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003 Jun-Aug;24(3-4):233-40. PMID: 14523363. https://pubmed.ncbi.nlm.nih.gov/14523363/ Hermánek J, Prokopic J. Influence of thymic preparations on the result of experimental infection with Taenia crassiceps (Zeder, 1800) in ICR mice. Folia Parasitol (Praha). 1989;36(4):331-40. https://pubmed.ncbi.nlm.nih.gov/2488049/ Bach JF, Dardenne M. Thymulin, a zinc-dependent hormone. Med Oncol Tumor Pharmacother. 1989;6(1):25-9. doi: 10.1007/BF02985220. PMID: 2657247. https://pubmed.ncbi.nlm.nih.gov/2657247/ National Center for Biotechnology Information. "PubChem Compound Summary for CID 3085284, Nonathymulin" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Nonathymulin Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Pal-GHK (200mg)
Palmitoyl-GHK, also known as palmitoyl-tripeptide-1, is a synthetic hybrid molecule consisting of a chain of three amino acids attached to a palmitic acid molecule. The GHK sequence, which consists of the amino acids Gly-His-Lys, is found naturally in plasma, discovered in 1973 by Pickart et al.(1) The addition of palmitoyl to the molecule is thought to result in better penetration through the stratum corneum of the epidermal barrier.(2) The palmitoyl group, which is a fatty acid chain, is thought to increase lipophilicity, which may potentially enhance the compatibility of the molecule with the lipid-rich environment of the stratum corneum. The added palmitoyl group might also act as a penetration enhancer by disrupting the tightly packed lipid structure of the stratum corneum. This disruption could temporarily loosen the lipid matrix, allowing Pal-GHK and other agents to permeate through various skin tissue models. Researchers have suggested that Pal-GHK may stimulate collagen production, a key component of the skin's extracellular matrix (ECM). This hypothesis was initially developed because the Gly-His-Lys sequence is also a structural fragment of the protein collagen. Gly-His-Lys is believed to be released during collagen hydrolysis, typically induced in tissue repair and to mitigate inflammation. Therefore, the tripeptide is believed to act as a natural feedback signal to fibroblasts, the cells responsible for producing collagen and other ECM components. Pal-GHK may also exhibit antioxidant potential against damage caused by free radicals. Free radicals are unstable molecules that may damage cell structures and are considered to contribute to the aging process. By potentially neutralizing free radicals, Palmitoyl-GHK may reduce cellular aging and inflammation. Chemical Makeup Molecular formula: C30H54N6O5 Molecular weight: 578.8 g/mol Other Known Titles: Palmitoyl Tripeptide-1, Palmitoyl oligopeptide, Biopeptide-CL Research and Clinical Studies Pal-GHK and Collagen Synthesis Research by Maquart et al. dating back to 1988 and published in the journal FEBS Letters suggests that the Gly-His-Lys in Pal-GHK is a fragment produced during the hydrolysis of collagen.(3) Such fragments are produced when collagen is damaged, and they may signal fibroblasts to initiate the process of collagen synthesis. Pal-GHK may have a similar potential to stimulate collagen, elastin, and glycosaminoglycans, important components of the extracellular matrix of the skin. The researchers concluded, "The presence of a GHK triplet in the alpha 2(I) chain of type I collagen suggests that the tripeptide might be liberated by proteases at the site of a wound and exert in situ healing effects." A placebo-controlled clinical study suggests that Pal-GHK may stimulate collagen synthesis, as concluded following the assessment of the apparent effect of the peptide on skin thickness. The trial involved twenty-three subjects, and the researchers reported a small but statistically significant increase in skin thickness of about 4% compared to the placebo.(5) Pal-GHK and Wrinkle Depth A clinical study was conducted to ascertain the peptide’s potential in reducing the depth and length of wrinkles along the stratum corneum. The study evaluated the action of the peptide in a cream form (6) and included fifteen subjects. The scientists reported an apparent reduction in wrinkle length, depth, and texture inconsistency (roughness) following the study period. Another clinical experiment involved a combination of Pal-GHK tripeptide and another palmitoylated peptide called Pal-GQPR.(7) Pal-GQPR is a tetrapeptide with the sequence of Pal-Gly-Gln-Pro-Arg, and it is a fragment of immunoglobulin G (IgG) which is considered to play an important role in reducing the amount of interleukin 6 (IL6) production. The design was a blind, randomized clinical study that included twenty-eight subjects. There was an apparent reduction of wrinkle depth, volume, density, texture inconsistency, and the area occupied by deep wrinkles following exposure to the combination of the two palmitoylated peptides. Pal-GHK and Antioxidation A 2018 laboratory experiment by Sakuma et al. suggested that the amino-acid sequence of Pal-GHK may have antioxidative potential.(8) The researchers also reported that this potential was apparently more powerful than other compounds classified as antioxidative and commonly used in research, such as carnosine and reduced glutathione. More specifically, the researchers shared that "Experiments utilizing an ESR spin-trapping technique revealed that, among hydroxyl (·OH), superoxide (O2-·), and peroxyl (ROO·) radicals generated by respective chemical reaction systems, GHK diminished signals of both ·OH and ROO·." Active radicals appear to be apparent mediators of photodamage. Examples of such active radicals include reactive oxygen species (ROS), reactive nitrogen species (RNS), and reactive carbonyl species (RCS), which are considered to cause harm to lipids, DNA, and proteins. Studies have suggested that the amino acid sequence found in Pal-GHK may potentially prevent protein glycation and may possess anti-RCS properties against various radicals like acrolein, malondialdehyde, and 4-hydroxynoneal.(9) Additionally, Pal-GHK has been suggested to have the potential to reduce the release of iron from ferritin, which catalyzes lipid peroxidation. In other words, Pal-GHK may lead to a lower rate of lipid peroxidation, ostensibly preserving the integrity of cell membranes and reducing cellular damage. In the context of skin tissue integrity, this might contribute to enhanced skin cell function and survival. One study shared results of an apparent 87% decrease in the iron release from damaged tissue using Pal-GHK, which appeared to have reduced oxidation in the affected tissues.(10) By potentially lowering lipid peroxidation, Pal-GHK might indirectly help mitigate the alteration of DNA and proteins, potentially reducing risk factors that may otherwise lead to cellular damage. Pal-GHK may also potentially reduce the production of reactive oxygen species and inflammatory cytokines while increasing the activity of antioxidant enzymes. During one experiment using a murine model, Pal-GHK was suggested to suppress the activation of Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) and p38 mitogen-activated protein kinase (MAPK) signaling pathways, both of which are associated with inflammation.(11) Pal-GHK might potentially inhibit the activation of p38 MAPK either by blocking the upstream kinases that activate it or by interfering with the signaling molecules that initiate its phosphorylation. The inhibition may conceivably suppress the inflammatory response, reducing the overall stress on cells. This may lead to reduced infiltration of inflammatory cells in the tissues of murine models of lung tissue damage and lower levels of TNF-1 and IL-6 production. Researchers have also speculated about Pal-GHK's potential to alleviate the oxidative stress of smoke inhalation. Research findings have led to the proposal that the amino-acid sequence of Pal-GHK might impede oxidative stress in alveolar epithelial cells by increasing Nrf2 (Nuclear factor erythroid 2-related factor 2) expression and reducing the levels of reactive oxygen species in cell cultures.(12) Nrf2 is a protein that may regulate the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation. Pal-GHK peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Pickart, L., & Thaler, M. M. (1973). Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature: New biology, 243(124), 85–87. Gorouhi, F., & Maibach, H. I. (2009). Role of peptides in preventing or treating aged skin. International journal of cosmetic science, 31(5), 327-345. Maquart, F. X., Pickart, L., Laurent, M., Gillery, P., Monboisse, J. C., & Borel, J. P. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS letters, 238(2), 343–346. https://doi.org/10.1016/0014-5793(88)80509-x Trookman, N. S., Rizer, R. L., Ford, R., Mehta, R., & Gotz, V. (2009). Clinical assessment of a combination lip treatment to restore moisturization and fullness. The Journal of clinical and aesthetic dermatology, 2(12), 44–48. Lintner, K., & Peschard, O. (2000). Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. International journal of cosmetic science, 22(3), 207–218. https://doi.org/10.1046/j.1467-2494.2000.00010.x Schagen, S. K. (2017). Peptide treatments with effective anti-aging results. Cosmetics, 4(2), 16. Fournial, A., & Mondon, P. New Cosmetic or Dermopharmaceutical Use of a Mixture of a Ghk Tripeptide and Gqpr Tetrapeptide. Sakuma, S., Ishimura, M., Yuba, Y., Itoh, Y., & Fujimoto, Y. (2018). The peptide glycyl-ʟ-histidyl-ʟ-lysine is an endogenous antioxidant in living organisms, possibly by diminishing hydroxyl and peroxyl radicals. International journal of physiology, pathophysiology and pharmacology, 10(3), 132–138. Cebrián, J., Messeguer, A., Facino, R. M., & García Antón, J. M. (2005). New anti-RNS and -RCS products for cosmetic treatment. International journal of cosmetic science, 27(5), 271–278. https://doi.org/10.1111/j.1467-2494.2005.00279.x Park, J. R., Lee, H., Kim, S. I., & Yang, S. R. (2016). The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget, 7(36), 58405–58417. https://doi.org/10.18632/oncotarget.11168 Sakuma, S., Ishimura, M., Yuba, Y., Itoh, Y., & Fujimoto, Y. (2018). The peptide glycyl-ʟ-histidyl-ʟ-lysine is an endogenous antioxidant in living organisms, possibly by diminishing hydroxyl and peroxyl radicals. International journal of physiology, pathophysiology and pharmacology, 10(3), 132–138. Zhang, Q., Yan, L., Lu, J., & Zhou, X. (2022). Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Frontiers in molecular biosciences, 9, 925700. https://doi.org/10.3389/fmolb.2022.925700 Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
PE-22-28 (8mg)
PE-22-28 is a synthetic derivative of the naturally occurring protein called spadin.(1) Spadin is a natural peptide derived from sortilin, an abundant protein in the central nervous system. PE-22-28 peptide is one such shortened peptide derivative of this protein; similar to spadin, PE-22-28 research indicates it primarily acts via the TREK-1 receptor. Researchers Djillani et al. commented that PE-22–28 may be "the shortest, most efficient sequence capable of blocking the TREK-1 channel" and may have a potentially higher potency in research settings than spadin.(2) TREK-1 (TWIK-related potassium channel) receptor is a two-pore potassium channel recently identified as a potential target for studying and modifying animal models of depression. In 2010, research(3) suggested that when TREK-1 receptors were removed from murine models, they became more resistant to depression. TREK-1 receptor is primarily found in the brain region, including the prefrontal cortex and hippocampus, i.e., areas governing mood, memory, and learning. Simulating the TREK-1 receptor may reduce neuron excitability, whereas reducing the receptor activity may increase neuron excitability.(4) While mainly evaluated in the study of depression models, this receptor may also play a strong role in anesthesia, pain perception, and protection of neurons. Overview Studies(1) have suggested that naturally occurring spadin blocks the TREK-1 channel, possibly exerting antidepressant activity for a specific duration. In order to improve the compound’s bioavailability and stability, scientists conducted several studies on spadin derivatives and analogs. One such study(1) was conducted on the seven amino acid spadin derivatives called PE-22-28. More specifically, the peptide corresponds to the chain from the 22nd to 28th amino acids of the original spadin sequence; hence, the reason behind the name PE-22-28. Similar to spadin, researchers theorized that these synthetic derivatives might bind to the TREK-1 channel, blocking activity and thereby producing mind stability and mood enhancement. Chemical Makeup Molecular Formula: C35H55N11O9 Molecular Weight: 773.89 g/mol Sequence: GVSWGLR Research and Clinical Studies PE-22-28 Peptide and Depression Researchers have suggested brain models of depression exhibit a smaller volume in the hippocampus. When presented with the PE-22-28 compound, the smaller volume may be increased and brought to an optimal threshold, potentially mitigating instances of synaptic feedback that lead to depressive episodes. Researchers propose that the peptide may have antidepressant potential through its proposed action in neurogenesis, which is supported by the cAMP signal cascade mechanism.(5) PE-22-28 Peptide and Post Stroke Depression (PSD) A study(4) was conducted where the experimental mice, induced with PSD, were presented with either the spadin peptide, or an SSRI compound (selective serotonin reuptake inhibitors). An SSRI, as the name suggests, is an antidepressant that is considered to prevent the reabsorption of serotonin neurotransmitters. While both compounds reportedly exhibited improvements in the mice, SSRIs may induce a wide range of additional unintended impacts, while PE-22-28 peptide is hypothesized not to. The SSRI compound also reportedly took longer to exhibit any action while the peptide was apparently fast-acting. PE-22-28 Peptide and Neurogenesis Studies have suggested that the peptide may exert neurogenesis (formation of neurons) and synaptogenesis (formation of synapses). Studies(6) were conducted where spadin derivatives were exposed in neuron cultures of mouse tissues. One study conducted in 2010 indicated subsequent MAPK and PI3K pathway activation, which might lead to neuron protection and formation. The other study suggested the peptide's potential to increase mRNA expression and concentration of brain-derived neurotrophic factor (BDNF) in the hippocampus.The hippocampus is considered critical in learning and memory processes. Hence, studies suggest that PE-22-28 may exhibit nootropic potential via possible action in the hippocampus region. Over time, organisms may exhibit a decline or downregulation of transcription factor cAMP response element-binding protein (CREB) activity in the brain, i.e., cAMP response element binding activity. CREB is considered critical for the growth and formation of neurons and may support memory recall and neuronal plasticity.(7) The findings of this 2010 study also suggested that spadin appeared to increase the number of bromodeoxyuridine (BrdU) positive cells in the hippocampus compared to saline-treated mice, hinting that PE-22-28, an analog of spadin, may potentially induce similar hippocampal neurogenesis. BrdU is considered a thymidine analog that integrates into the DNA of proliferating cells during the S-phase of the cell cycle, serving as a marker for cell division. Spadin apparently induced a rapid increase in BrdU-positive cells within 4 days, suggesting a quick activation of neurogenic pathways. This action persisted with long-term experimentation (15 days). As mentioned, a key component of spadin's rapid action might involve the activation of CREB, which may involve a specific link between CREB activation and hippocampal neurogenesis. The research analysis indicated that 4-day experimentation with spadin led to an apparent increase in phosphorylated CREB (pCREB), with levels four times higher than those seen in saline-treated controls. This phosphorylation suggests activation of CREB, confirmed by Western blot analysis showing the active form of CREB, while total CREB levels remained constant. Furthermore, the researchers observed a significant colocalization of pCREB with doublecortin (DCX), a marker of neuronal precursors, suggesting that CREB activation might be closely linked with the neurogenic process, specifically affecting neuronal rather than glial cells. These observations suggest that spadin, potentially through rapid CREB activation, may significantly enhance both the extent and speed of hippocampal neurogenesis, raising the possibility that PE-22-28 might similarly influence neurogenesis through these pathways.(3) PE-22-28 Peptide and Muscle Function TREK-1 receptor is also considered to impact muscles' ability to respond to outer stimulation. Upon stimulation, this receptor reportedly induces relaxation of the muscles, and consequently, blocks the receptors may lead to muscle contraction. Based on this understanding of the receptor, the PE-22-28 peptide is involved in ongoing research to establish its correlation with muscle relaxation and contraction.(8) PE-22-28 Peptide and Serotonin Signaling As mentioned, studies suggest that PE-22-28 may act as a blocker of the TREK-1 channel, akin to its natural analog spadin. This hypothesis is bolstered by research exploring these potential actions, particularly focusing on the connectivity between the medial prefrontal cortex (mPFC) and dorsal raphé serotonergic neurons in experimental models. The researchers observed that spadin might stimulate serotonin neurons and noted that the actions of spadin combined with serotonin agonists appeared additive, operating independently. Notably, adding a mGluR2/3 antagonist was suggested to inhibit the action of spadin, pointing towards a dependency of spadin on mPFC TREK-1 channels that are possibly linked to mGluR2/3 receptors. Consequently, it seems plausible that PE-22-28 may similarly interact with mGluR2/3 receptors, promoting the activation of serotonin neurons in a parallel fashion to spadin. Further investigations using immunohistochemical labeling revealed apparent interactions between spadin and the selective serotonin agonist RS 67333's actions on Zif268 expression in the dorsal raphé nucleus (DRN), indicating both additive and synergistic actions. Specifically, while individual concentrations of spadin or RS 67333 appeared to increase the number of Zif268-positive cells, their combination elevated these numbers dramatically, suggesting a strong depolarization of a subset of DRN neurons. Experiments involving the mGluR2/3 antagonist LY 341495 indicated that these may enhance the average firing rate of DRN serotonin neurons, a result that was abolished by an electrolytic lesion of the mPFC. This finding further implicates the mPFC TREK-1 channels linked to mGluR2/3 receptors regulating serotonin neuron activity. These observations are complemented by fluorescence microscopy studies using the ratiometric dye Fura2-AM to measure intracellular Ca2+ levels in cultured cortical neurons. The data posits that experiments combining spadin with LY 341495 or RS 67333 may increase intracellular Ca2+ levels compared to control or single exposures, with the most pronounced actions observed with the RS 67333 combination. This potentiation may be dependent on the stimulation of serotonin receptors, as blocking these receptors with GR 125487 appeared to eliminate the synergistic actions observed with RS 67333. Collectively, these findings underline a complex interplay between TREK-1 channel activity, mGluR2/3 receptor interaction, and serotonin neuron firing, mediated through the mPFC. The data suggest that spadin (and potentially PE-22-28 as a spadin-analog) may leverage these molecular mechanisms to influence serotonergic signaling, highlighting a nuanced interdependency between these pathways.(9) Indeed, scientists have theorized that by inhibiting TREK-1, PE-22–28 may increase serotonin transmission. They have commented that when “PE-22-28 is [presented to] the dorsal raphé nucleus, the peptide will block the channel and thereby activate the serotonergic neurons, resulting in the facilitation of serotonergic transmission”.(10) PE-22-28 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Djillani A, Pietri M, Moreno S, Heurteaux C, Mazella J, Borsotto M. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol. 2017 Sep 12;8:643. https://pubmed.ncbi.nlm.nih.gov/28955242/ Djillani, A., Pietri, M., Mazella, J., Heurteaux, C., & Borsotto, M. (2019). Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin. Pharmacology & therapeutics, 194, 185–198. https://doi.org/10.1016/j.pharmthera.2018.10.003 Mazella J, Pétrault O, Lucas G, Deval E, Béraud-Dufour S, Gandin C, El-Yacoubi M, Widmann C, Guyon A, Chevet E, Taouji S, Conductier G, Corinus A, Coppola T, Gobbi G, Nahon JL, Heurteaux C, Borsotto M. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol. 2010 Apr 13;8(4):e1000355. https://pubmed.ncbi.nlm.nih.gov/20405001/ Djillani, A., Mazella, J., Heurteaux, C., & Borsotto, M. (2019). Role of TREK-1 in Health and Disease, Focus on the Central Nervous System. Frontiers in pharmacology, 10, 379. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470294/ Duman, R., Nakagawa, S. & Malberg, J. Regulation of Adult Neurogenesis by Antidepressant Treatment. Neuropsychopharmacol 25, 836–844 (2001). https://doi.org/10.1016/S0893-133X(01)00358-X Devader C, Khayachi A, Veyssière J, Moha Ou Maati H, Roulot M, Moreno S, Borsotto M, Martin S, Heurteaux C, Mazella J. In vitro and in vivo regulation of synaptogenesis by the novel antidepressant spadin. Br J Pharmacol. https://pubmed.ncbi.nlm.nih.gov/25598009/ Mental health: spadin, a fast-acting antidepressant. https://journals.biologists.com/dmm/article/3/7-8/398/2435/Mental-health-spadin-a-fast-acting-antidepressant Lei Q, Pan XQ, Chang S, Malkowicz SB, Guzzo TJ, Malykhina AP. Response of the human detrusor to stretch is regulated by TREK-1, a two-pore-domain (K2P) mechano-gated potassium channel. J Physiol. 2014 Jul 15;592(14):3013-30. https://pubmed.ncbi.nlm.nih.gov/24801307 Moha ou Maati, Hamid et al. “The peptidic antidepressant spadin interacts with prefrontal 5-HT(4) and mGluR(2) receptors in the control of serotonergic function.” Brain structure & function vol. 221,1 (2016): 21-37. doi:10.1007/s00429-014-0890-x Okada, Masayoshi, and Ernesto Ortiz. "Viral vector-mediated expressions of venom peptides as novel gene therapy for anxiety and depression." Medical Hypotheses 166 (2022): 110910. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Ipamorelin (5mg)
Ipamorelin is a synthetic peptide that is composed of five amino acids, otherwise known as a pentadecapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), formally classified as a Growth Hormone Secretagogue (GHS). Its name is derived from the intention of its development. Ipamorelin peptide was designed to act via ghrelin receptor binding. The ghrelin receptors on the pituitary gland (the gland naturally involved with growth hormone, or hGH synthesis) are also known as Growth Hormone Secretagogue receptors (GHS-R). Through its implied action, Ipamorelin may host the potential to trigger the GHS-Rs on the pituitary gland and potentially stimulate the release of growth hormone.(1) Overview Ipamorelin is the first synthetic GHS that appears highly selective and may have the potential to augment the production of hGH without affecting other pituitary hormones such as prolactin or adrenocorticotropic hormone (ACTH). The potential increase in hGH might promote lipolysis and insulin-like growth factor-1 (IGF-1) production synthesis. Consequently, IGF-1 may become a mediator of hGH’s anabolic actions, and thereby the peptide may act to increase cellular proliferation and bone and muscle anabolism.(1) Chemical Makeup Molecular Formula: C38H49N9O5 Molecular Weight: 711.86 g/mol Other Known Titles: NNC 26-0161 Research and Clinical Studies Ipamorelin Peptide and Selective Agonism Based on one 1998 murine model-based research study, researchers suggested that Ipamorelin may release growth hormones from the pituitary cells. When Ipamorelin was presented to swine and pentobarbitone anesthetized rats, it reportedly exhibited release in growth hormones. Upon further observation, the researchers hypothesized that similar to other growth hormone (GH) stimulating peptides, Ipamorelin may be a growth receptor agonist stimulating GH release through potential affinity in growth hormone receptors. Moreover, the researchers commented that Ipamorelin appears to be the first GHS-R “agonist with a selectivity for GH release similar to that displayed by GHRH. The specificity of Ipamorelin makes this compound a very interesting candidate for future clinical development.”(1) Scientific research studies have also suggested that Ipamorelin may lead to increased hGH secretion, possibly without significantly affecting other pituitary hormones such as the levels of prolactin or ACTH.(2) Ipamorelin Peptide and Growth Hormone Synthesis Studies conducted in vitro suggest that the interaction of Ipamorelin with GHS receptors may potentially affect somatotroph cells in the anterior pituitary gland by triggering a series of cellular signaling events.(3) This theorized pathway involves the activation of phospholipase C (PLC), which some researchers believe may lead to the increased release of inositol triphosphate (IP3) and diacylglycerol (DAG). This release of secondary messenger molecules such as IP3 might potentially stimulate the discharge of calcium ions (Ca2+) from the cell's internal stores, while DAG might activate protein kinase C (PKC). The subsequent rise in intracellular calcium levels and the possible activation of PKC are thought to result in the exocytosis of vesicles filled with growth hormones from these pituitary cells.(3) In late 1999, a clinical trial was carried out on eight test subjects where Ipamorelin was presented every 15 minutes for a set period. Two hours post-study, it was suggested by the researchers that the levels of growth hormone had apparently increased. More specifically, Ipamorelin appeared to have tended to boost growth hormone levels, potentially soaring to as much as 80mIU/l (roughly equivalent to a concentration of about 26.6ng/ml). When this increase is measured as a percentage compared to a placebo (with a baseline of 1.31mIU/l or 0.4ng/ml), the enhancement appeared to have exceeded a 60-fold uplift.(4) Ipamorelin Peptide and Bone Tissue It is conceivable that Ipamorelin may positively influence bone mineral density. The theory posits that Ipamorelin might stimulate osteoblasts (cells responsible for bone formation) via hGH-mediated mechanisms, potentially leading to their enhanced proliferation, growth, and specialization. In a particular study, murine models were exposed to either Ipamorelin or a placebo.(5) The impact of Ipamorelin on bone mineral density in these mice was monitored closely through real-time dual X-ray absorptiometry (DEXA) assessments at critical sites, including the femur and L6 vertebra. Post-experiment, the femur bones were further examined using mid-diaphyseal peripheral quantitative computed tomography (pQCT) scans. Preliminary findings implied that the peptide may have contributed to increased body mass and a probable elevation in the overall tibial and vertebral BMC (bone mineral content) as detected by DEXA compared to the placebo group. Further, the pQCT data appeared to suggest that the observed augmentation in cortical BMC may have stemmed from an enlargement in the cross-sectional area of the bone. In contrast, the cortical volumetric bone mineral density (BMD, which denotes the ratio of BMC to area) appeared to remain steady. Thus, there may have been an enlargement in the volumes of the femur and the L6 vertebrae since BMC appeared to increase while the volumetric BMDs appeared unchanged.(5) Ipamorelin Peptide and Digestion Researchers have delved into the potential of Ipamorelin in the functionality of the stomach, with a keen interest in its ability to possibly expedite the process of gastric emptying. For example, one study employed a technique to ascertain gastric emptying rates, which entailed monitoring the proportion of a marked substance that lingered in the stomach 15 minutes after its introduction through intragastric gavage.(6) The scientists conducted surgeries to purposefully decelerate the gastric emptying process in murine models. This deceleration was particularly noticeable in the control group. In contrast, Ipamorelin appeared to have markedly accelerated the emptying process compared to the control. This observation led the team to hypothesize that Ipamorelin might be able to increase the velocity of gastric emptying. Additional research was initiated to delve deeper into the action of the compound on the contractile potential of the stomach's smooth muscles, which were activated by acetylcholine and electrical field stimulation. Indeed, the decelerated peristalsis appeared to be mitigated when Ipamorelin and ghrelin were studied together, suggesting the idea that Ipamorelin may enhance the contractility of gastric smooth muscles.(6) Ipamorelin Peptide and Appetite The potential actions of Ipamorelin on ghrelin receptors may lead to an enhancement in hunger signals and, perhaps, an ensuing augmentation in body mass. Research suggests that research models exposed to Ipamorelin were observed to sustain an estimated 15% surge in body weight.(7) Researchers speculate that this substance might have led to a proportional increase in the weight of fat pads in comparison to the total body weight. Consequently, DEXA scans might indicate a comparative rise in body fat percentage. Moreover, there is speculation among researchers that Ipamorelin might elevate serum leptin levels, a hormone considered to play a crucial role in energy balance and hunger regulation. This observation has prompted scientists to consider increased food consumption as a potential contributor to the weight gain noted in research models exposed to Ipamorelin. They have posited that "GHSs increase body fat by GH-independent mechanisms that may include increased feeding.”(7) Ipamorelin Peptide and Nitrogen Balance Researchers have suggested that Ipamorelin may potentially mediate anabolic action, which may be due to its potential in hGH and IGF-1 synthesis and may be assessed through its impact on nitrogen balance. In a distinct investigation, researchers aimed to explore the action of Ipamorelin on specific liver markers associated with alpha-amino-nitrogen conversion during induced catabolic states.(8) The study focused on the liver’s capacity to synthesize urea-N (CUNS), which may serve as an indicator of the organ's ability to process nitrogen. The levels of messenger RNA (mRNA) related to liver urea cycle enzymes were scrutinized, alongside an assessment of the overall nitrogen balance and a hypothesis regarding nitrogen distribution across various organs. The findings suggested that Ipamorelin might have contributed to a possible 20% reduction in CUNS compared to the artificially induced catabolic condition. Furthermore, it might have diminished the expression of urea cycle enzymes, possibly restored nitrogen balance, and, in theory, altered or improved nitrogen concentrations in different organs.(8) Ipamorelin peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: K. Raun et al., Ipamorelin, the first selective growth hormone secretagogue, Endocrinology, November 1998. Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108996/ Jiménez-Reina, L., Cañete, R., de la Torre, M. J., & Bernal, G. (2002). Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 17(3), 707–714. https://doi.org/10.14670/HH-17.707 Gobburu, J.V.S., Agersø, H., Jusko, W.J. et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharm Res 16, 1412–1416 (1999). Svensson, J., Lall, S., Dickson, S. L., Bengtsson, B. A., Rømer, J., Ahnfelt-Rønne, I., Ohlsson, C., & Jansson, J. O. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. The Journal of endocrinology, 165(3), 569–577. https://doi.org/10.1677/joe.0.1650569 Greenwood-Van Meerveld, B., Tyler, K., Mohammadi, E., & Pietra, C. (2012). Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology, 4, 149–155. https://doi.org/10.2147/JEP.S35396 Lall, S., Tung, L. Y., Ohlsson, C., Jansson, J. O., & Dickson, S. L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications, 280(1), 132–138. https://doi.org/10.1006/bbrc.2000.4065 Aagaard, N. K., Grøfte, T., Greisen, J., Malmlöf, K., Johansen, P. B., Grønbaek, H., Ørskov, H., Tygstrup, N., & Vilstrup, H. (2009). Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society, 19(5), 426–431. https://doi.org/10.1016/j.ghir.2009.01.001 Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Vialox (Pentapeptide-3V) (200mg)
Vialox, or pentapeptide-3, is a synthetic peptide molecule with the amino acid sequence GPRPA. It is believed to work by blocking neuronal nicotinic acetylcholine receptors located in the postsynaptic membrane of muscle cells. These receptors transmit signals from nerve cells to muscle cells, resulting in muscle contraction. By potentially reducing the release of acetylcholine, Vialox may relax muscles, reducing wrinkle depth and development along the skin barrier. The mechanism of action of Vialox may be similar to that of tubocurarine, a natural alkaloid compound considered to have muscle-relaxing activity. Chemical Makeup Molecular Formula: C21H37N9O5 Molecular Weight: 495.58 g/mol Other Known Titles: Pentapeptide-3V, SCHEMBL1552457, HY-P0099, ZINC35922739 Research and Clinical Studies Vialox Peptide Mechanism of Action Vialox is a synthetic peptide molecule suggested by researchers to be an inhibitor of neurotransmitter activity.(1) Vialox may act in a manner that is similar to that of tubocurarine, specifically through its interaction with acetylcholine receptors located on the postsynaptic membrane of muscle cells.(2) Tubocurarine is a naturally occurring alkaloid compound found in the bark of certain plants, particularly in the species Chondrodendron tomentosum, commonly known as "curare." It is considered to be a potent neurotoxin that appears to act as a non-depolarizing neuromuscular blocker by blocking the action of acetylcholine at the neuromuscular junction, thereby preventing muscle contraction. Researchers also classify Vialox as a non-depolarizing neuromuscular blocker. The peptide appears to bind to the acetylcholine receptors on the postsynaptic membrane of muscle cells. By doing so, studies report that it acts as "a competitive antagonist at the acetylcholine postsynaptic membrane receptor."(3) The peptide may possibly interact with the neuronal nicotinic acetylcholine receptors. Nicotinic acetylcholine receptors reportedly play a crucial role in regulating muscle contraction by serving as the primary receptor in muscles for the communication between motor nerves and muscles at the neuromuscular junction. As an antagonist, Vialox appears to block the binding of acetylcholine to these receptor sites, thereby preventing the opening of the sodium ion channels responsible for depolarizing the cell and normally leading to muscle contraction.(4) By inhibiting the activity of the acetylcholine receptors, Vialox may cause the smooth muscles to stay relaxed, reducing wrinkles and fine lines in the skin. Vialox Peptide and Wrinkle Development, Skin Texture Vialox has been researched for its potential to reduce wrinkles upon the skin surface, and decrease texture variations along the skin barrier. There are some risks associated with using compounds to induce wrinkle reduction, particularly when used in higher concentrations or for extended periods. Furthermore, there is some concern that long-term exposure may have unknown or unanticipated impact. However, Vialox appears to have a short half-life and may be introduced less invasively. Nevertheless, it may be impactful, as researchers report that "studies [...] showed that this [compound] softened wrinkles and reduced skin roughness(4). These researchers reported that the tests appeared to result in reduced muscle contractions by 71% within one minute after Vialox presentation, leading to a 58% reduction two hours later. Ultimately, the scientists suggested that the reduced frequency of muscle contractions has the potential to result in shallower lines along the surface of the skin barrier. According to research, the peptide may also potentially mitigate the impact of skin wrinkles.(9) The results of the study indicate a noticeable decrease of 49% in the size of wrinkles, accompanied by a 47% decrease in the roughness of the skin within a time frame of 28 days of consistent presentation. Vialox peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Husein el Hadmed, H., & Castillo, R. F. (2016). Cosmeceuticals: peptides, proteins, and growth factors. Journal of cosmetic dermatology, 15(4), 514-519. Lupo, M. P., & Cole, A. L. (2007). Cosmeceutical peptides. Dermatologic therapy, 20(5), 343-349. Gorouhi, F., & Maibach, H. I. (2009). Role of peptides in preventing or treating aged skin. International journal of cosmetic science, 31(5), 327-345. Satriyasa B. K. (2019). Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. Clinical, cosmetic and investigational dermatology, 12, 223–228. https://doi.org/10.2147/CCID.S202919 Kalandakanond, S., & Coffield, J. A. (2001). Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. The Journal of pharmacology and experimental therapeutics, 296(3), 980–986. Bakheit A. M. (2006). The possible adverse effects of intramuscular botulinum toxin injections and their management. Current drug safety, 1(3), 271–279. https://doi.org/10.2174/157488606777934431 Witmanowski, H., & Błochowiak, K. (2020). The whole truth about botulinum toxin - a review. Postepy dermatologii i alergologii, 37(6), 853–861. https://doi.org/10.5114/ada.2019.82795 Reddy, B. Y., Jow, T., & Hantash, B. M. (2012). Bioactive oligopeptides in dermatology: Part II. Experimental dermatology, 21(8), 569-575. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
MOTS-C (10mg)
MOTS-c (mitochondrial open-reading-frame of the 12S rRNA-c) peptide is a novel mitochondria-derived peptide. It is a short peptide composed of 16 amino acids, expressed in tissues and plasma, indicating a cell-specific and hormonal role.(1) With the potential to work both as a cell-specific compound and as a hormone, this peptide possibly acts by stimulating the AMP-activated protein kinase (AMPK) pathway. Only two mitochondrial-derived peptides (MDPs) have been studied, Humanin and MOTS-c. When metabolic stress occurs in the organism, the peptide is believed to translocate to the cellular nuclei and alter the gene expression. MOTS-c peptide may also be released extracellularly and is known as "mitochondrial hormone" or simply as "mitokine.”(2)(3) Chemical Makeup(4) Molecular Formula: C101H152N28O22S2 Molecular Weight: 2174.64 g/mol Other Titles: Mitochondrial-derived peptide MOTS-c, Mitochondrial open reading frame of the 12S rRNA-c Research and Clinical Studies Animal research models have indicated multiple potential actions from MOTS-c peptide, including increased physical performance, regulated cellular and tissue metabolism, and myoblast adaptation.(2) Research suggests that these actions may primarily depend on age and age-related changes in MOTS-c expression. The researchers suggest MOTS-c levels and activity might decline, hinting at a role in the cell aging process and the development of age-related metabolic dysfunction. Furthermore, MOTS-c may interact with known aging regulators, such as NAD+ and sirtuins, suggesting its involvement in pathways potentially modulating the lifespan of the cell.(1) As per Joseph C Reynolds et al., “Mitochondria are chief metabolic organelles with strong implications in cell aging that also coordinate broad physiological functions, in part, using peptides that are encoded within their independent genome.”(4) The peptide endogenous expression has also been posited to be boosted via physical activity, potentially enhancing cellular metabolism.(5) MOTS-c Peptide and Muscle Metabolism With increasing age, skeletal muscles tend to gain insulin resistance, leading to decreased glucose uptake. Upon peptide exposure, skeletal muscles may be stimulated with an improved response toward AMPK activation. As a result, glucose transporter expression may increase, potentially improving skeletal muscle metabolism and enhancing skeletal muscle functioning and growth. Further, MOTS-c's actions are posited to include targeting metabolic pathways such as the folate-methionine cycle and purine biosynthesis. This targeting may potentially lead to a modulation of cellular metabolism, including actions on glucose uptake and lipid utilization. The peptide's impact might involve a shift in metabolic priorities within the cell, possibly affecting the balance between anabolic and catabolic processes. In systemic metabolism, MOTS-c is posited to function as a mitochondrial hormone, with circulating peptide levels appearing to affect metabolic functions in skeletal muscle and possibly adipose tissue. Its potential regulatory actions on glucose homeostasis and insulin action suggest a broader hormonal role in energy balance and nutrient sensing across different tissues.(1) MOTS-c Peptide and Fat Cell Metabolism Research has suggested that the peptide may potentially leave the mitochondrial site, translocate to cellular nuclei, and possibly alter gene expression. More specifically, the peptide may interact with a broad range of genes, particularly those with antioxidant response elements (ARE), hinting at a potential regulatory relationship with stress-responsive transcription factors like NRF2. Such findings suggest a genetically integrated system of mitonuclear communication, where both mitochondrial and nuclear genomes may encode factors that cross-regulate each other. This action, in turn, may alter glucose uptake restriction.(6) This hypothesis was first suggested from a study in which the experimental mice were given high-fat food, and only half were presented with the peptide. The researchers indicated that MOTS-c may potentially impact cellular metabolism by inhibiting the folate cycle directly tethered de novo purine biosynthesis, consequently leading to AMPK activation. Such actions hint at a broader role of the peptide in regulating insulin sensitivity and metabolic homeostasis, offering insights into its preventive potential against age-dependent and high-fat-induced insulin resistance and diet-induced obesity. The study presents supportive data to suggest that the peptide may stimulate glucose utilization, affect the methionine-folate cycle, and promote AMPK activation. These cellular actions suggest that MOTS-c might coordinate various metabolic processes, including glucose and lipid metabolism. Consequently, the murine models exposed to the peptide were lean and more energetic than the rest, further indicating that the peptide might prevent fat accumulation and induce glucose uptake via the AMPK pathway.(3) MOTS-c Peptide and Bone MOTS-c peptide has been suggested to regulate the transforming growth factor beta (TGF-beta)/SMAD pathway, which may profoundly affect bone tissues.(7) More specifically, MOTS-c's actions may involve the upregulation of TGF-β/Smad pathway-related genes, including TGF-β1, TGF-β2, and Smad7, suggesting a pivotal role of this pathway in MOTS-c mediated osteogenic differentiation. This hypothesis is further supported when the osteogenic differentiation promoted by MOTS-c is reversed upon TGF-β1 knockdown, indicating that MOTS-c's actions may be at least partly mediated through the TGF-β/Smad pathway. The peptide may also stimulate the expression of osteogenesis-related genes such as ALP, Bglap, and Runx2. Thus, this peptide may stimulate the SMAD pathway in the osteoblast cells, possibly improving bone density and strength. When studied in bone marrow cells, this compound appeared to trigger the differentiation of the stem cells, which may lead to bone tissue development. MOTS-c Peptide and Cardiac Function The peptide has not been suggested by researchers to directly influence cardiac function; instead, researchers posit that the peptide exerts potential on the endothelial cells that line the blood vessels inside. These endothelial tissues are considered to affect blood pressure and clotting. The researchers suspect a positive correlation exists between MOTS-c levels and microvascular and epicardial endothelial function. Such findings tentatively suggest MOTS-c as a potential biomarker for endothelial function, with the study revealing a nuanced relationship between MOTS-c levels and vascular reactivity. Further, the research suggested that when mice were exposed to MOTS-c, it appeared to improve the endothelial tissues' functioning, thereby possibly facilitating dysfunction. The mechanistic basis for MOTS-c's action on endothelial function remains speculative but may involve the activation of AMPK.(8) MOTS-c Peptide and Cell Lifespan Research has suggested that the peptide may be associated with enhanced longevity on a cellular level. The peptide typically contains glutamate residue, but when this is replaced by lysine, the new compound may exert a functional change. Scientists so far are aware that the functionality of the glutamate and lysine groups are vastly different, but how this specific structural change affects peptide functionality is yet to be understood. Noriyuki Fuku et al. suggests that there is “a biological link between MOTS-c and extended lifespan through the putative endocrine action of this mitokine. Further mechanistic research is needed to determine the functional significance of polymorphism and the potential influence of MOTS-c in the [...] aging process.” (9) The peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016 Nov;100:182-187. doi: 10.1016/j.freeradbiomed.2016.05.015. Epub 2016 May 20. PMID: 27216708; PMCID: PMC5116416. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116416/ Mohtashami Z, Singh MK, Salimiaghdam N, Ozgul M, Kenney MC. Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. Int J Mol Sci. 2022 Oct 9;23(19):11991. doi: 10.3390/ijms231911991. PMID: 36233287; PMCID: PMC9570330. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015 Mar 3;21(3):443-54. doi: 10.1016/j.cmet.2015.02.009. PMID: 25738459; PMCID: PMC4350682. Lu H, Wei M, Zhai Y, Li Q, Ye Z, Wang L, Luo W, Chen J, Lu Z. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. J Mol Med (Berl). 2019 Apr;97(4):473-485. doi: 10.1007/s00109-018-01738-w. Epub 2019 Feb 6. PMID: 30725119. https://pubmed.ncbi.nlm.nih.gov/30725119/ Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021 Jan 20;12(1):470. https://pubmed.ncbi.nlm.nih.gov/33473109/ Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018 Sep 4;28(3):516-524.e7. doi: 10.1016/j.cmet.2018.06.008. Epub 2018 Jul 5. PMID: 29983246; PMCID: PMC6185997. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185997/ Hu BT, Chen WZ. MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway. Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7156-7163. doi: 10.26355/eurrev_201811_16247. PMID: 30468456. https://pubmed.ncbi.nlm.nih.gov/30468456/ Qin Q, Delrio S, Wan J, Jay Widmer R, Cohen P, Lerman LO, Lerman A. Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. Int J Cardiol. 2018 Mar 1;254:23-27. doi: 10.1016/j.ijcard.2017.12.001. Epub 2017 Dec 6. PMID: 29242099. https://pubmed.ncbi.nlm.nih.gov/29242099/ Noriyuki Fuku el al., The mitochondrial-derived peptide: A player in exceptional longevity?, http://dx.doi.org/10.1111/acel.12389. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.